Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week ...
At close: February 13 at 4:00:02 PM EST ...
The P vector may arise from either (a) a sidereal diurnal variation, (b) an annual solar variation, or (c) a combination of these effects. This communication discusses the interpretation to be placed ...
Find out the direct holders, institutional holders and mutual fund holders for Apogee Enterprises, Inc. (APOG).
Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results